Asia-Pacific Bipolar Disorder Market

Asia-Pacific Bipolar Disorder Market Size

The size of the Asia-Pacific bipolar disorder market was valued at USD 0.51 billion in 2024 and is anticipated to reach USD 0.59 billion by 2033, growing at a CAGR of 1.66% from 2024 to 2033.

MARKET DRIVERS

Rising Prevalence, Tech Integration, and Awareness Initiatives Drive APAC Bipolar Disorder Market

The Asia-Pacific bipolar disorder market drivers include the growing prevalence of bipolar disorder, the presence of a large population, and supportive initiatives by government institutes to increase awareness. In addition, various risk factors such as high stress, substance abuse, and others will aggravate bipolar disorders. According to estimates from the Global Burden of Disease, the prevalence of bipolar disorder worldwide ranges from 0.33 to 1.28% per country. In 2017, approximately 47 million people had bipolar disorder, and 52% were males, and 48% were women in the report. Most patients with the disorder have a history of depression. The likelihood of both men and women being affected by bipolar disorder is similar. Hence, the increase in the diagnosed disease cases will need an effective and optimal treatment plan.

Additionally, technological advancements in smartphones, smartwatches, and wearable devices improve diagnostic rates by effectively capturing physiological, behavioral, and environmental data to detect a patient's mood and mental state. Online self-management tools also enable rapid intervention, improving diagnosis and rates of treatment for the disease. Scientific bodies and medical institutions also actively conduct studies and develop new drugs with successful clinical data and research. For example, the Salk Institute for Biological Studies and the Johns Hopkins University of Medicine launched a $ 15.4 million initiative to develop new drug testing studies for bipolar disorder and schizophrenia.

MARKET RESTRAINTS

Patent Expiry, Side Effects, and Stigma Hamper APAC Bipolar Disorder Market Growth

The expiration of the patents of highly effective drugs in this market is likely to affect the market dynamics during the forecast period. Moreover, the drugs in the market face intense competition due to black-market goods. Studies have also linked some drugs to serious side effects, such as kidney failure and teratogenic changes in the fetus if used by pregnant women. Other factors that may slow the market's growth include side effects associated with anticonvulsants, misdiagnosis of bipolar disorder, strict regulatory frameworks, the limited number of approved drugs, and social stigma. For instance, the treatment gap rate for people with mental disorders is unacceptably high in China, with 91.85% of all people diagnosed with mental disorders never seeking treatment.

REPORT COVERAGE

COUNTRY LEVEL ANALYSIS

Geographically, the Chinese bipolar disorder market is expected to grow at a healthy CAGR during the forecast period and adds significant potential to the Asia-Pacific market in terms of exploitable opportunities for selecting budding companies and their savvy leaders. This regional market is anticipated to grow due to the large population, genetic predisposition, and improving public awareness programs. According to the Black Dog Institute, bipolar disorder is linked to the genetic disease of an individual. If parents have bipolar disorder, their children will likely suffer from the same condition in the future. According to data released by the WHO, India and China are among the countries most affected by mental disorders such as schizophrenia, bipolar disorder, and anxiety. In addition to government initiatives such as the Healthy Asia Pacific 2020 initiative, launched by the Asia-Pacific Economic Cooperation body, they are likely to stimulate the market in this region.

Other Asia-Pacific regional markets in India, Japan, Thailand, South Korea, and Australia will also have a steady CAGR during the forecast period, attributed to the high prevalence of mental disorders in the years to come.

KEY MARKET PLAYERS

Companies playing a promising role in the Asia-Pacific bipolar disorder market profiled in this report are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc.

MARKET SEGMENTATION

This research report on the Asia-Pacific bipolar disorder market has been segmented and sub-segmented into the following categories.

By Method

• Genotypic
• Proteomics-based
• Phenotypic

By Application

• F&B
• Diagnostic
• Pharmaceutical
• Environmental

By Product

• Identification Services
• Consumables
• Instruments

By End User

• Food Manufacturing Industries
• Pharmaceutical Companies
• Hospitals and Diagnostic Centres
• Other End-users

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of Asia-Pacific